Press Coverage

Safety Watchdog Questions FDA's Approval of Parkinson's Psychosis Drug

Article describes findings from an ISMP QuarterWatch report that reviewed documents from the FDA's evaluation of pimavanserin (Nuplazid), a drug approved to treat Parkinson's disease patients with psychosis, and found a number of questions about the drug's safety and efficacy have been left unanswered. The report calls for stronger warnings on the drug label and a re-evaluation of whether Nuplazid has benefits that outweigh its still poorly defined risks.

For the full text, visit CNN online.

More News

ECRI Institute and the Institute for Safe Medication Practices (ISMP) announce the successful completion of their plans to join forces. Effective today, ISMP is an ECRI Institute affiliate. By joining together, the two patient safety leaders have created one of the largest healthcare quality and